ECSP14030537A - Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 - Google Patents
Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1Info
- Publication number
- ECSP14030537A ECSP14030537A ECIEPI201430537A ECPI201430537A ECSP14030537A EC SP14030537 A ECSP14030537 A EC SP14030537A EC IEPI201430537 A ECIEPI201430537 A EC IEPI201430537A EC PI201430537 A ECPI201430537 A EC PI201430537A EC SP14030537 A ECSP14030537 A EC SP14030537A
- Authority
- EC
- Ecuador
- Prior art keywords
- abl1
- bcr
- activity
- abl2
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se ref iere a los compuestos de la fórmula ( I ) : en donde Y, Y1 , R1 , R2, R3 y R4 se def inen en la Breve Descr ipción de la Invención; capaces de inhibi r la act ividad de BCR-ABL1 y los mutantes de los mismos. La invención proporciona además un proceso para la preparación de los compuestos de la invención, las preparaciones farmacéut icas que comprenden estos compuestos, y los métodos para ut i l izar tales compuestos en el t ratamiento de cánceres.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644616P | 2012-05-09 | 2012-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP14030537A true ECSP14030537A (es) | 2015-09-30 |
Family
ID=48444372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201430537A ECSP14030537A (es) | 2012-05-09 | 2014-12-08 | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 |
Country Status (24)
Country | Link |
---|---|
US (2) | US20150087808A1 (es) |
EP (1) | EP2847211A1 (es) |
JP (3) | JP2015517481A (es) |
KR (1) | KR20150006435A (es) |
CN (2) | CN104284902A (es) |
AR (1) | AR090964A1 (es) |
AU (2) | AU2013257989A1 (es) |
BR (1) | BR112014027648A2 (es) |
CA (1) | CA2868940A1 (es) |
CL (1) | CL2014003014A1 (es) |
CO (1) | CO7141428A2 (es) |
EA (1) | EA024903B1 (es) |
EC (1) | ECSP14030537A (es) |
HK (1) | HK1202555A1 (es) |
IL (1) | IL235428A0 (es) |
IN (1) | IN2014DN08483A (es) |
MA (1) | MA20150231A1 (es) |
MX (1) | MX2014013613A (es) |
PE (1) | PE20142433A1 (es) |
PH (1) | PH12014502499A1 (es) |
SG (1) | SG11201406303XA (es) |
TN (1) | TN2014000411A1 (es) |
TW (1) | TW201350508A (es) |
WO (1) | WO2013167703A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693820A (zh) * | 2014-11-27 | 2016-06-22 | 武汉药明康德新药开发有限公司 | 一种降解环孢菌素a的方法 |
EP3623378A4 (en) | 2017-05-12 | 2021-03-03 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF MAKING A CYCLIC ORGANIC COMPOUND |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT401177B (de) | 1993-10-22 | 1996-07-25 | Biochemie Gmbh | Verfahren zur herstellung von 7-amino-3-cephem-4-carbonsäure-derivaten |
ATE312843T1 (de) * | 1998-07-01 | 2005-12-15 | Debiopharm Sa | Neues cyclosporin mit verbesserter wirkung |
ATE330968T1 (de) * | 1999-02-05 | 2006-07-15 | Debiopharm Sa | Cyclosporin-derivate und verfahren zu deren herstellung |
RU2290196C2 (ru) * | 2001-04-20 | 2006-12-27 | Дебиофарм С.А. | Модифицированный циклоспорин, который можно использовать в качестве пролекарства, и его применение |
WO2003033526A2 (en) * | 2001-10-19 | 2003-04-24 | Isotechnika Inc. | Synthesis of cyclosporin analogs |
TW200505946A (en) | 2003-04-08 | 2005-02-16 | Hoffmann La Roche | Process for preparation of cyclosporin a analog |
ES2357587T3 (es) | 2004-10-01 | 2011-04-27 | Debiopharm S.A. | Uso de (d-meala)3-(etval)4-ciclosporina para el tratamiento de infección por hepatitis c. |
US20060223743A1 (en) * | 2004-12-17 | 2006-10-05 | Mark Abel | Metabolites of cyclosporin analogs |
EP2124992A2 (en) | 2007-01-04 | 2009-12-02 | Debiopharm S.A. | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
EP2195009B1 (en) | 2007-09-26 | 2014-07-30 | Oregon Health and Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
US7910378B2 (en) * | 2007-12-14 | 2011-03-22 | Siemens Healthcare Diagnostics Inc. | Methods for detection of hydrophobic drugs |
WO2009098533A1 (en) | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
JP5758806B2 (ja) | 2008-11-06 | 2015-08-05 | デビオ ルシェルシュ ファルマスーティク ソシエテ アノニムDebio Recherche Pharmaceutique Societe Anonyme | シクロウンデカデプシペプチド化合物および医薬としてのその化合物の使用 |
CA2748389A1 (en) * | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
EP2391376A4 (en) * | 2009-01-30 | 2012-08-01 | Enanta Pharm Inc | ANALOGUES OF CYCLOSPORIN FOR PREVENTING OR TREATING HEPATITIS C INFECTION |
WO2012021796A2 (en) * | 2010-08-12 | 2012-02-16 | S&T Global, Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
-
2013
- 2013-05-07 AR ARP130101557A patent/AR090964A1/es unknown
- 2013-05-08 CA CA2868940A patent/CA2868940A1/en not_active Abandoned
- 2013-05-08 PE PE2014001983A patent/PE20142433A1/es not_active Application Discontinuation
- 2013-05-08 EP EP13722740.1A patent/EP2847211A1/en not_active Withdrawn
- 2013-05-08 CN CN201380023760.8A patent/CN104284902A/zh active Pending
- 2013-05-08 IN IN8483DEN2014 patent/IN2014DN08483A/en unknown
- 2013-05-08 US US14/399,261 patent/US20150087808A1/en not_active Abandoned
- 2013-05-08 CN CN201810575515.2A patent/CN108715606A/zh active Pending
- 2013-05-08 EA EA201492036A patent/EA024903B1/ru not_active IP Right Cessation
- 2013-05-08 TW TW102116414A patent/TW201350508A/zh unknown
- 2013-05-08 JP JP2015510823A patent/JP2015517481A/ja not_active Withdrawn
- 2013-05-08 KR KR1020147031112A patent/KR20150006435A/ko not_active Application Discontinuation
- 2013-05-08 AU AU2013257989A patent/AU2013257989A1/en not_active Abandoned
- 2013-05-08 SG SG11201406303XA patent/SG11201406303XA/en unknown
- 2013-05-08 MA MA37498A patent/MA20150231A1/fr unknown
- 2013-05-08 MX MX2014013613A patent/MX2014013613A/es unknown
- 2013-05-08 BR BR112014027648A patent/BR112014027648A2/pt not_active IP Right Cessation
- 2013-05-08 WO PCT/EP2013/059672 patent/WO2013167703A1/en active Application Filing
-
2014
- 2014-09-30 TN TNP2014000411A patent/TN2014000411A1/fr unknown
- 2014-10-30 IL IL235428A patent/IL235428A0/en unknown
- 2014-11-07 CL CL2014003014A patent/CL2014003014A1/es unknown
- 2014-11-10 CO CO14248207A patent/CO7141428A2/es unknown
- 2014-11-10 PH PH12014502499A patent/PH12014502499A1/en unknown
- 2014-12-08 EC ECIEPI201430537A patent/ECSP14030537A/es unknown
-
2015
- 2015-03-20 HK HK15102858.0A patent/HK1202555A1/xx unknown
-
2016
- 2016-06-30 US US15/198,152 patent/US9840534B2/en not_active Expired - Fee Related
- 2016-08-31 AU AU2016222370A patent/AU2016222370B2/en not_active Ceased
-
2017
- 2017-08-29 JP JP2017164867A patent/JP2018035154A/ja not_active Withdrawn
-
2019
- 2019-09-30 JP JP2019179311A patent/JP2020033349A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016222370A1 (en) | 2016-09-15 |
PE20142433A1 (es) | 2015-02-02 |
WO2013167703A1 (en) | 2013-11-14 |
JP2018035154A (ja) | 2018-03-08 |
IL235428A0 (en) | 2014-12-31 |
CO7141428A2 (es) | 2014-12-12 |
WO2013167703A9 (en) | 2014-11-20 |
BR112014027648A2 (pt) | 2017-06-27 |
TW201350508A (zh) | 2013-12-16 |
KR20150006435A (ko) | 2015-01-16 |
CN104284902A (zh) | 2015-01-14 |
TN2014000411A1 (en) | 2015-12-21 |
IN2014DN08483A (es) | 2015-05-08 |
US9840534B2 (en) | 2017-12-12 |
JP2015517481A (ja) | 2015-06-22 |
MX2014013613A (es) | 2015-02-12 |
AU2013257989A1 (en) | 2014-10-23 |
SG11201406303XA (en) | 2014-11-27 |
CA2868940A1 (en) | 2013-11-14 |
US20160304554A1 (en) | 2016-10-20 |
AR090964A1 (es) | 2014-12-17 |
CL2014003014A1 (es) | 2015-03-06 |
EA024903B1 (ru) | 2016-10-31 |
EA201492036A1 (ru) | 2015-02-27 |
CN108715606A (zh) | 2018-10-30 |
EP2847211A1 (en) | 2015-03-18 |
JP2020033349A (ja) | 2020-03-05 |
PH12014502499A1 (en) | 2014-12-22 |
MA20150231A1 (fr) | 2015-07-31 |
US20150087808A1 (en) | 2015-03-26 |
AU2016222370B2 (en) | 2017-10-05 |
HK1202555A1 (en) | 2015-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2014000256A (es) | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 | |
BR112014027181A2 (pt) | derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1 | |
MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
MX357305B (es) | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. | |
NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
IN2014MN01754A (es) | ||
EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
NZ749911A (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
CR20130371A (es) | IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS | |
NI201600014A (es) | Compuestos y composiciones como inhibidores de la mek. | |
IN2014MN02106A (es) | ||
MX2015009950A (es) | Compuestos de imidazopiridina y sus usos. | |
BR112013018515A2 (pt) | derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase | |
NZ703162A (en) | Heterocyclic modulators of lipid synthesis | |
EA201301319A1 (ru) | Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний | |
EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
ECSP14030537A (es) | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 | |
CU20100250A7 (es) | Compuestos pirazólicos 436 |